Advertisement
Advertisement
RDY
Dr. Reddy's Laboratories Limited - ADR
13.51
USDSponsored
-0.09
-0.70%
May 19, 12:37 UTC -4
Open
RDY Earnings Reports
Positive Surprise Ratio
RDY beat 23 of 41 last estimates.
56%
Next Report
Date of Next Report
Jul 21, 2026
Estimate for Q1 27 (Revenue/ EPS)
$78.53B
/$10.30
Implied change from Q4 26 (Revenue/ EPS)
+4.06%
/+288.68%
Implied change from Q1 26 (Revenue/ EPS)
-8.39%
/-39.48%
Dr. Reddy's Laboratories Limited - ADR earnings per share and revenue
On May 12, 2026, RDY reported earnings of 2.65 USD per share (EPS) for Q4 26, missing the estimate of 11.40 USD, resulting in a -76.76% surprise. Revenue reached 75.46 billion, compared to an expected 84.10 billion, with a -10.27% difference. The market reacted with a +4.25% price change (close before vs. close after earnings).
Looking ahead to Q1 27, 3 analysts forecast an EPS of 10.30 USD, with revenue projected to reach 78.53 billion USD, implying an increase of 288.68% EPS, and increase of 4.06% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
BridgeBio Pharma, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.69
Actual
-$0.84
Surprise
-21.37%
Supernus Pharmaceuticals, Inc.
Report Date
May 05, 2026 For Q1 26
Estimate
$0.30
Actual
$0.60
Surprise
+97.69%
Taysha Gene Therapies, Inc. Common Stock
Report Date
May 06, 2026 For Q1 26
Estimate
-$0.09
Actual
-$0.12
Surprise
-20.48%
Amphastar Pharmaceuticals, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
$0.71
Actual
$0.42
Surprise
-41.59%
Personalis, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-5.42%
Assembly Biosciences, Inc
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.58
Actual
-$0.54
Surprise
+7.12%
Metagenomi Therapeutics, Inc. Common Stock
Report Date
May 11, 2026 For Q1 26
Estimate
-$0.53
Actual
-$0.61
Surprise
-14.68%
FAQ
What were Dr. Reddy's Laboratories Limited - ADR's earnings and revenue for the latest quarter Q4 2026?
For Q4 2026, Dr. Reddy's Laboratories Limited - ADR reported EPS of $2.65, missing estimates by -76.76%, and revenue of $75.46B, -10.27% below expectations.
How did the market react to Dr. Reddy's Laboratories Limited - ADR's Q4 2026 earnings?
The stock price moved up 4.25%, changed from $12.46 before the earnings release to $12.99 the day after.
When is Dr. Reddy's Laboratories Limited - ADR expected to report next?
The next earning report is scheduled for Jul 21, 2026.
What are the forecasts for Dr. Reddy's Laboratories Limited - ADR's next earnings report?
Based on 3
analysts, Dr. Reddy's Laboratories Limited - ADR is expected to report EPS of $10.30 and revenue of $78.53B for Q1 2027.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement